NL1024499A1 - Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen. - Google Patents
Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen.Info
- Publication number
- NL1024499A1 NL1024499A1 NL1024499A NL1024499A NL1024499A1 NL 1024499 A1 NL1024499 A1 NL 1024499A1 NL 1024499 A NL1024499 A NL 1024499A NL 1024499 A NL1024499 A NL 1024499A NL 1024499 A1 NL1024499 A1 NL 1024499A1
- Authority
- NL
- Netherlands
- Prior art keywords
- treatment
- neurodegenerative disorders
- thiazole compounds
- thiazole
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41740002P | 2002-10-09 | 2002-10-09 | |
| US41740002 | 2002-10-09 | ||
| US46320903A | 2003-06-17 | 2003-06-17 | |
| US46320903 | 2003-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL1024499A1 true NL1024499A1 (nl) | 2004-04-13 |
| NL1024499C2 NL1024499C2 (nl) | 2004-10-13 |
Family
ID=35306299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL1024499A NL1024499C2 (nl) | 2002-10-09 | 2003-10-09 | Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20040152747A1 (nl) |
| EP (1) | EP1551815A1 (nl) |
| JP (1) | JP2006504796A (nl) |
| KR (1) | KR20050070046A (nl) |
| CN (1) | CN1688557A (nl) |
| AP (1) | AP2005003274A0 (nl) |
| AR (1) | AR043051A1 (nl) |
| AU (1) | AU2003265068A1 (nl) |
| BR (1) | BR0314611A (nl) |
| CA (1) | CA2501803A1 (nl) |
| CO (1) | CO5550435A2 (nl) |
| CR (1) | CR7785A (nl) |
| EC (1) | ECSP055719A (nl) |
| GT (1) | GT200300219A (nl) |
| IS (1) | IS7738A (nl) |
| MA (1) | MA27451A1 (nl) |
| MX (1) | MXPA05002420A (nl) |
| NL (1) | NL1024499C2 (nl) |
| NO (1) | NO20052223L (nl) |
| OA (1) | OA12937A (nl) |
| PA (1) | PA8585001A1 (nl) |
| PE (1) | PE20040640A1 (nl) |
| PL (1) | PL376171A1 (nl) |
| TN (1) | TNSN05104A1 (nl) |
| TW (1) | TW200420550A (nl) |
| UY (1) | UY28011A1 (nl) |
| WO (1) | WO2004033439A1 (nl) |
| ZA (1) | ZA200502841B (nl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| CA2524511A1 (en) * | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| WO2005016267A2 (en) * | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Oxazole compounds for the treatment of neurodegenerative disorders |
| FR2873374B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| ATE517098T1 (de) | 2004-01-16 | 2011-08-15 | Sanofi Sa | Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren |
| BRPI0506880A (pt) * | 2004-01-16 | 2007-06-26 | Sanofi Aventis | derivados de acilaminotiazol, sua preparação e sua aplicação em terapêutica |
| FR2865207B1 (fr) * | 2004-01-16 | 2008-10-17 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2873370B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2865206B1 (fr) * | 2004-01-16 | 2009-02-06 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| CN1934091B (zh) * | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7384968B2 (en) | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| CA2608153C (en) | 2005-05-24 | 2014-09-23 | Laboratoires Serono S.A. | Thiazole derivatives for use as p13k modulators |
| FR2887879B1 (fr) * | 2005-07-01 | 2008-09-26 | Trophos Sa | Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives |
| BRPI0616141A2 (pt) * | 2005-09-22 | 2011-06-07 | Pfizer Prod Inc | compostos imidazol para o tratamento de distúrbios neurológicos |
| US8105581B2 (en) | 2005-12-01 | 2012-01-31 | The Scripps Research Institute | Compositions and methods for inducing neuronal differentiation |
| BRPI0706621A2 (pt) * | 2006-01-18 | 2011-04-05 | Amgen Inc | composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto |
| ATE538108T1 (de) * | 2006-11-05 | 2012-01-15 | Max Planck Gesellschaft | Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| US7919504B2 (en) * | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| KR20110028661A (ko) | 2008-07-15 | 2011-03-21 | 노파르티스 아게 | Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체 |
| WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
| WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| CN102351854B (zh) * | 2011-07-29 | 2014-06-04 | 华中科技大学 | 氨基噻唑衍生物及制备方法和医药用途 |
| CN105143222B (zh) * | 2013-03-14 | 2018-02-02 | 默克专利有限公司 | 糖苷酶抑制剂 |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| TW201906838A (zh) * | 2017-06-21 | 2019-02-16 | 日商第一三共股份有限公司 | Ｅｐ３００／ｃｒｅｂｂｐ抑制劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06508135A (ja) * | 1991-05-28 | 1994-09-14 | メルク エンド カンパニー インコーポレーテッド | 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体 |
| SK16282000A3 (sk) * | 1998-05-01 | 2001-05-10 | Abbott Laboratories | Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2 |
| CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
| AU6229699A (en) * | 1998-10-26 | 2000-05-15 | Sumitomo Pharmaceuticals Company, Limited | Beta-amyloid formation inhibitors |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
-
2003
- 2003-09-29 EP EP03807933A patent/EP1551815A1/en not_active Withdrawn
- 2003-09-29 KR KR1020057006168A patent/KR20050070046A/ko not_active Application Discontinuation
- 2003-09-29 BR BR0314611-1A patent/BR0314611A/pt not_active IP Right Cessation
- 2003-09-29 MX MXPA05002420A patent/MXPA05002420A/es not_active Application Discontinuation
- 2003-09-29 CN CNA038240106A patent/CN1688557A/zh active Pending
- 2003-09-29 AP AP2005003274A patent/AP2005003274A0/xx unknown
- 2003-09-29 WO PCT/IB2003/004330 patent/WO2004033439A1/en active Application Filing
- 2003-09-29 PL PL03376171A patent/PL376171A1/xx not_active Application Discontinuation
- 2003-09-29 AU AU2003265068A patent/AU2003265068A1/en not_active Abandoned
- 2003-09-29 CA CA002501803A patent/CA2501803A1/en not_active Abandoned
- 2003-09-29 OA OA1200500098A patent/OA12937A/en unknown
- 2003-09-29 JP JP2005501002A patent/JP2006504796A/ja active Pending
- 2003-10-03 TW TW092127495A patent/TW200420550A/zh unknown
- 2003-10-07 PE PE2003001021A patent/PE20040640A1/es not_active Application Discontinuation
- 2003-10-08 PA PA20038585001A patent/PA8585001A1/es unknown
- 2003-10-08 AR ARP030103662A patent/AR043051A1/es unknown
- 2003-10-08 US US10/682,686 patent/US20040152747A1/en not_active Abandoned
- 2003-10-09 GT GT200300219A patent/GT200300219A/es unknown
- 2003-10-09 UY UY28011A patent/UY28011A1/es not_active Application Discontinuation
- 2003-10-09 NL NL1024499A patent/NL1024499C2/nl not_active IP Right Cessation
-
2005
- 2005-03-10 IS IS7738A patent/IS7738A/is unknown
- 2005-04-07 EC EC2005005719A patent/ECSP055719A/es unknown
- 2005-04-07 CR CR7785A patent/CR7785A/es not_active Application Discontinuation
- 2005-04-08 MA MA28206A patent/MA27451A1/fr unknown
- 2005-04-08 CO CO05031337A patent/CO5550435A2/es not_active Application Discontinuation
- 2005-04-08 TN TNP2005000104A patent/TNSN05104A1/fr unknown
- 2005-05-06 NO NO20052223A patent/NO20052223L/no unknown
-
2006
- 2006-01-17 ZA ZA200502841A patent/ZA200502841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL376171A1 (en) | 2005-12-27 |
| CA2501803A1 (en) | 2004-04-22 |
| BR0314611A (pt) | 2005-07-26 |
| MA27451A1 (fr) | 2005-07-01 |
| TNSN05104A1 (fr) | 2007-05-14 |
| AU2003265068A1 (en) | 2004-05-04 |
| EP1551815A1 (en) | 2005-07-13 |
| GT200300219A (es) | 2004-05-18 |
| UY28011A1 (es) | 2004-04-30 |
| NL1024499C2 (nl) | 2004-10-13 |
| NO20052223D0 (no) | 2005-05-06 |
| ZA200502841B (en) | 2006-03-29 |
| AR043051A1 (es) | 2005-07-13 |
| WO2004033439A1 (en) | 2004-04-22 |
| IS7738A (is) | 2005-03-10 |
| CN1688557A (zh) | 2005-10-26 |
| PA8585001A1 (es) | 2004-12-16 |
| NO20052223L (no) | 2005-07-04 |
| CO5550435A2 (es) | 2005-08-31 |
| AP2005003274A0 (en) | 2005-06-30 |
| ECSP055719A (es) | 2005-07-06 |
| KR20050070046A (ko) | 2005-07-05 |
| MXPA05002420A (es) | 2005-10-05 |
| OA12937A (en) | 2006-10-13 |
| PE20040640A1 (es) | 2004-09-15 |
| US20040152747A1 (en) | 2004-08-05 |
| TW200420550A (en) | 2004-10-16 |
| CR7785A (es) | 2005-07-08 |
| JP2006504796A (ja) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL1024499A1 (nl) | Thiazoolverbindingen voor de behandeling van neurodegeneratieve stoornissen. | |
| NL1026892A1 (nl) | ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie. | |
| NL1028598A1 (nl) | Imidazoolverbindingen voor de behandeling van neurodegeneratieve ziekten. | |
| NL1026329A1 (nl) | 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten. | |
| NL1028599A1 (nl) | Verbindingen voor de behandeling van ziekten. | |
| NL1028086A1 (nl) | Sulfonamidederivaten voor de behandeling van ziekten. | |
| NL1030418A1 (nl) | Azabenzoxazolen voor de behandeling van CZS-stoornissen. | |
| NL1026327A1 (nl) | 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten. | |
| NL1028087A1 (nl) | Sulfonamiderivaten voor de behandeling van ziekten. | |
| NL1025071A1 (nl) | Verbindingen voor de behandeling van abnormale celgroei. | |
| NL1026203A1 (nl) | Verbindingen toepasbaar voor de behandeling van ziekten. | |
| NO20053211D0 (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
| NO20043237L (no) | Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser | |
| EP1643986A4 (en) | PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| NO20053384L (no) | Benzazepinderivater for behandling av neurologiske forstyrrelser. | |
| NL1028924A1 (nl) | Gesubstitueerde morfolineverbindingen voor de behandeling van stoornissen van het centrale zenuwstelsel. | |
| NL1023695A1 (nl) | Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water. | |
| NL1023692A1 (nl) | Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water. | |
| NL1028664A1 (nl) | Sulfonamideverbindingen voor de behandeling van neurodegeneratieve ziekten. | |
| NL1023691A1 (nl) | Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water. | |
| NL1023694A1 (nl) | Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water. | |
| EP1658072A4 (en) | Compounds for the Treatment of Neurodegenerative Diseases | |
| NL1033562A1 (nl) | Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie. | |
| EP1734957A4 (en) | THIAZOLE SULFAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| NL1032552C2 (nl) | Imidazoolverbindingen voor de behandeling van neurologische stoornissen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AD1A | A request for search or an international type search has been filed | ||
| RD2N | Patents in respect of which a decision has been taken or a report has been made (novelty report) |
Effective date: 20040610 |
|
| PD2B | A search report has been drawn up | ||
| VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20080501 |